Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03597464 · ClinicalTrials.gov registry record · Phase 3
Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin
A Phase 3 study, sponsored by Aurinia Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 216
- Enrollment target
NCT03597464 is a Phase 3 study that has completed, run by Aurinia Pharmaceuticals. The registered enrollment target is 216 participants.
The verdict
NCT03597464, a Phase 3 study, has completed, sponsored by Aurinia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 216 participants
- Enrollment target
Study Summary
The purpose of this study is assess the long-term safety and tolerability of voclosporin compared with placebo for up to an additional 24 months following completion of treatment in the AURORA 1 study in subjects with lupus nephritis (LN).
Interventions
- DRUG Placebo Oral Capsule
- DRUG Voclosporin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2019-09-29 |
| Est. Completion | 2021-10-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03597464
The ClinicalTrials.gov registry entry for NCT03597464 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aurinia Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Capsule is the first listed.
NCT03597464 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03597464 about?
NCT03597464 is a clinical study titled "Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin". The purpose of this study is assess the long-term safety and tolerability of voclosporin compared with placebo for up to an additional 24 months following completion of treatment in the AURORA 1 study in subjects with lupus nephritis (LN).
What is the current status of trial NCT03597464?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 216 participants. The study started on 2019-09-29. Estimated completion is 2021-10-07.
What interventions are being tested in trial NCT03597464?
The interventions under investigation include: Placebo Oral Capsule (DRUG), Voclosporin (DRUG).
Who is sponsoring clinical trial NCT03597464?
This trial is sponsored by Aurinia Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.